Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval?

Gemma E. Craig, Sarah D. Brown, Dimitrios A. Lamprou, Duncan Graham, Nial J. Wheate

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Gold nanoparticles (AuNPs) can be used as delivery vehicles for platinum anticancer drugs, improving their targeting and uptake into cells. Here, we examine the appropriateness of different-sized AuNPs as components of platinum-based drug-delivery systems, investigating their controlled synthesis, reproducibility, consistency of drug loading, and stability. The active component of cisplatin was tethered to 25, 55, and 90 nm AuNPs, with the nanoparticles being almost spherical in nature and demonstrating good batch-to-batch reproducibility (24.37 +/- 0.62, 55.2 +/- 1.75, and 89.1 +/- 2.32 nm). The size distribution of 25 nm AuNPs has been significantly improved, compared with a previous method that produces polydispersed nanoparticles. Attachment of platinum to the AuNP surface through a poly(ethylene glycol) (PEG) linker exhibits an increase in the drug loading with increasing particle size: 25 nm (815 +/- 106 drug molecules per AuNP), SS nm (14216 +/- 880), and 90 nm (54487 +/- 15996). The stability of the naked, PEGylated, and platinum-conjugated nanoparticles has been examined over time under various conditions. When stored at 4 degrees C, there is minimal variation in the diameter for all three AuNP sizes; variation after 28 days for the 25 nm AuNPs was 2.4%; 55 nm, 3.3%; and 90 nm, 3.6%. The 25 nm AuNPs also demonstrate minimal changes in UV-visible absorbance over the same time period.

LanguageEnglish
Pages3490-3497
Number of pages8
JournalInorganic Chemistry
Volume51
Issue number6
Early online date5 Mar 2012
DOIs
Publication statusPublished - 19 Mar 2012

Fingerprint

Platinum
Gold
Cisplatin
drugs
gold
Nanoparticles
platinum
nanoparticles
Pharmaceutical Preparations
Polyethylene glycols
delivery
Particle size
attachment
glycols
vehicles
ethylene
Molecules
synthesis
cells
molecules

Keywords

  • gold nanoparticles
  • anticancer drugs
  • drug-delivery systems

Cite this

Craig, Gemma E. ; Brown, Sarah D. ; Lamprou, Dimitrios A. ; Graham, Duncan ; Wheate, Nial J. / Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability : a step closer to pharmaceutical approval?. In: Inorganic Chemistry. 2012 ; Vol. 51, No. 6. pp. 3490-3497.
@article{b869f99f72eb478db53dfcfd2ab4137a,
title = "Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval?",
abstract = "Gold nanoparticles (AuNPs) can be used as delivery vehicles for platinum anticancer drugs, improving their targeting and uptake into cells. Here, we examine the appropriateness of different-sized AuNPs as components of platinum-based drug-delivery systems, investigating their controlled synthesis, reproducibility, consistency of drug loading, and stability. The active component of cisplatin was tethered to 25, 55, and 90 nm AuNPs, with the nanoparticles being almost spherical in nature and demonstrating good batch-to-batch reproducibility (24.37 +/- 0.62, 55.2 +/- 1.75, and 89.1 +/- 2.32 nm). The size distribution of 25 nm AuNPs has been significantly improved, compared with a previous method that produces polydispersed nanoparticles. Attachment of platinum to the AuNP surface through a poly(ethylene glycol) (PEG) linker exhibits an increase in the drug loading with increasing particle size: 25 nm (815 +/- 106 drug molecules per AuNP), SS nm (14216 +/- 880), and 90 nm (54487 +/- 15996). The stability of the naked, PEGylated, and platinum-conjugated nanoparticles has been examined over time under various conditions. When stored at 4 degrees C, there is minimal variation in the diameter for all three AuNP sizes; variation after 28 days for the 25 nm AuNPs was 2.4{\%}; 55 nm, 3.3{\%}; and 90 nm, 3.6{\%}. The 25 nm AuNPs also demonstrate minimal changes in UV-visible absorbance over the same time period.",
keywords = "gold nanoparticles , anticancer drugs, drug-delivery systems",
author = "Craig, {Gemma E.} and Brown, {Sarah D.} and Lamprou, {Dimitrios A.} and Duncan Graham and Wheate, {Nial J.}",
year = "2012",
month = "3",
day = "19",
doi = "10.1021/ic202197g",
language = "English",
volume = "51",
pages = "3490--3497",
journal = "Inorganic Chemistry",
issn = "0020-1669",
publisher = "American Chemical Society",
number = "6",

}

Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability : a step closer to pharmaceutical approval? / Craig, Gemma E.; Brown, Sarah D.; Lamprou, Dimitrios A.; Graham, Duncan; Wheate, Nial J.

In: Inorganic Chemistry, Vol. 51, No. 6, 19.03.2012, p. 3490-3497.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability

T2 - Inorganic Chemistry

AU - Craig, Gemma E.

AU - Brown, Sarah D.

AU - Lamprou, Dimitrios A.

AU - Graham, Duncan

AU - Wheate, Nial J.

PY - 2012/3/19

Y1 - 2012/3/19

N2 - Gold nanoparticles (AuNPs) can be used as delivery vehicles for platinum anticancer drugs, improving their targeting and uptake into cells. Here, we examine the appropriateness of different-sized AuNPs as components of platinum-based drug-delivery systems, investigating their controlled synthesis, reproducibility, consistency of drug loading, and stability. The active component of cisplatin was tethered to 25, 55, and 90 nm AuNPs, with the nanoparticles being almost spherical in nature and demonstrating good batch-to-batch reproducibility (24.37 +/- 0.62, 55.2 +/- 1.75, and 89.1 +/- 2.32 nm). The size distribution of 25 nm AuNPs has been significantly improved, compared with a previous method that produces polydispersed nanoparticles. Attachment of platinum to the AuNP surface through a poly(ethylene glycol) (PEG) linker exhibits an increase in the drug loading with increasing particle size: 25 nm (815 +/- 106 drug molecules per AuNP), SS nm (14216 +/- 880), and 90 nm (54487 +/- 15996). The stability of the naked, PEGylated, and platinum-conjugated nanoparticles has been examined over time under various conditions. When stored at 4 degrees C, there is minimal variation in the diameter for all three AuNP sizes; variation after 28 days for the 25 nm AuNPs was 2.4%; 55 nm, 3.3%; and 90 nm, 3.6%. The 25 nm AuNPs also demonstrate minimal changes in UV-visible absorbance over the same time period.

AB - Gold nanoparticles (AuNPs) can be used as delivery vehicles for platinum anticancer drugs, improving their targeting and uptake into cells. Here, we examine the appropriateness of different-sized AuNPs as components of platinum-based drug-delivery systems, investigating their controlled synthesis, reproducibility, consistency of drug loading, and stability. The active component of cisplatin was tethered to 25, 55, and 90 nm AuNPs, with the nanoparticles being almost spherical in nature and demonstrating good batch-to-batch reproducibility (24.37 +/- 0.62, 55.2 +/- 1.75, and 89.1 +/- 2.32 nm). The size distribution of 25 nm AuNPs has been significantly improved, compared with a previous method that produces polydispersed nanoparticles. Attachment of platinum to the AuNP surface through a poly(ethylene glycol) (PEG) linker exhibits an increase in the drug loading with increasing particle size: 25 nm (815 +/- 106 drug molecules per AuNP), SS nm (14216 +/- 880), and 90 nm (54487 +/- 15996). The stability of the naked, PEGylated, and platinum-conjugated nanoparticles has been examined over time under various conditions. When stored at 4 degrees C, there is minimal variation in the diameter for all three AuNP sizes; variation after 28 days for the 25 nm AuNPs was 2.4%; 55 nm, 3.3%; and 90 nm, 3.6%. The 25 nm AuNPs also demonstrate minimal changes in UV-visible absorbance over the same time period.

KW - gold nanoparticles

KW - anticancer drugs

KW - drug-delivery systems

UR - http://www.scopus.com/inward/record.url?scp=84858650268&partnerID=8YFLogxK

U2 - 10.1021/ic202197g

DO - 10.1021/ic202197g

M3 - Article

VL - 51

SP - 3490

EP - 3497

JO - Inorganic Chemistry

JF - Inorganic Chemistry

SN - 0020-1669

IS - 6

ER -